Can genomic classifiers close the gap between what we see and what a tumor will do? In this episode of BackTable Urology, Dr. Carissa Chu (UCSF) joins Dr. Ruchika Talwar (Vanderbilt) to explore how genomic classifiers are reshaping the way clinicians diagnose and manage bladder cancer.

---

This podcast is supported by:

Veracyte
https://www.veracyte.com/decipher-bladder

---

SYNPOSIS

They discuss the limitations of traditional staging systems and how molecular subtyping is providing deeper insight into tumor biology, treatment response, and prognosis. Dr. Chu highlights where these classifiers can be integrated into real-world clinical decision-making today, where the evidence is still emerging, and which ongoing trials may define the next era of precision medicine in urologic oncology.

---

TIMESTAMPS

0:00 - Introduction
3:01 - Overview of Genomic Classifiers
9:34 - Risk Stratification
15:22 - Current Evidence for Genomic Classifiers
22:07 - Clinical Implications of Biomarkers
27:23 - Ordering Genomic Classifiers
33:46 - Future Directions
37:57 - Final Takeaways

---

RESOURCES

Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers
https://pubmed.ncbi.nlm.nih.gov/38480079/

GUSTO Trial
https://fundingawards.nihr.ac.uk/award/NIHR128103